Categories Consumer, Earnings

Yeti beats market expectations for Q1, raises full-year outlook

YETI Holdings Inc. (NYSE: YETI) topped analysts’ estimates on revenue and earnings for the first quarter of 2019. Shares soared 9% in premarket hours on Thursday.

Net sales rose 15% year-over-year to $155.4 million. The sales results included a benefit of approx. 400 basis points from shipments late in the quarter that were expected to ship in the second quarter.

The company reported a net income of $2.2 million, or $0.03 per share, compared to a net loss of $3.3 million, or $0.04 per share, in the prior-year quarter. Adjusted net income was $6.6 million, or $0.08 per share.

Related: Yeti Holdings Q1 2019 Earnings Conference Call

Net sales in the Direct-to-consumer (DTC) channel jumped 28% to $61.7 million, driven by strong performance in the Drinkware category. In the Wholesale channel, net sales increased 8% to $93.6 million, primarily driven by Coolers & Equipment.

Drinkware net sales climbed 20% to $91 million, helped by the expansion of product offerings. Net sales in Coolers & Equipment grew 11% to $59.7 million, mainly driven by color updates across the hard and soft cooler lines, and the introduction of the CaminoTM Carryall bag to the wholesale channel.

Related: YETI Holdings Q4 2018 Earnings Report

Yeti updated its earnings outlook for the full year of 2019. GAAP EPS is now expected to be $0.87 to $0.90, reflecting 25% and 31% growth. Adjusted EPS is now expected to be $1.02 to $1.06, reflecting 13-17% growth.

The sales outlook remains unchanged and net sales for the year are expected to increase 11.5-13% compared to 2018, with growth across both channels and led by the DTC channel.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top